Compare NTZ & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTZ | KTTA |
|---|---|---|
| Founded | 1959 | 2020 |
| Country | Italy | United States |
| Employees | N/A | 5 |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.0M | 23.2M |
| IPO Year | 1998 | N/A |
| Metric | NTZ | KTTA |
|---|---|---|
| Price | $2.22 | $0.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 3.5K | ★ 408.8K |
| Earning Date | 04-13-2023 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $0.28 |
| 52 Week High | $3.95 | $2.06 |
| Indicator | NTZ | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 34.11 | 32.81 |
| Support Level | $2.16 | $0.54 |
| Resistance Level | $3.16 | $0.76 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 10.00 | 23.13 |
Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture, sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private Label, and Natuzzi Editions. The Group operates in two operating segments, the Natuzzi brand and Private label. The Natuzzi brand segment includes net sales from the Natuzzi Italia, Natuzzi Editions, and Divani&Divani by Natuzzi product lines. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.